Comparison
Lixisenatide vs. SNAP-8
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Cosmetic
CAS no.
320367-13-3
868844-74-0
Molecular weight
4858.5 g/mol
1075.16 g/mol
Half-life
3 h
no data
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2Mechanism of action
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
SNAP-8
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
3
of which in humans
5
1
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
1